TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24293578

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day of prednisolone for 6 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 125
Study: 22050499

Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 18801638

Group type: EXPERIMENTAL
Intervention: Educational intervention (intervention interview included an educational paragraph)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Current therapy for cardiac arrest (not specified as intervention or control)
Number of subjects: 473
Study: 18359543

Group type: EXPERIMENTAL
Intervention: Disruption of the magnocellular pathway through psychophysical manipulations (red background, equiluminant background, flicker or motion adaptation)
Number of subjects: 0
Study: 17042844

Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ilio-inguinal nerve block
Number of subjects: 80
Study: 12822009

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 6
Study: 10609592

Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 1600
Study: 7867183

Group type: EXPERIMENTAL
Intervention: c7E3 Fab 0.25 mg/kg
Number of subjects: 6
Study: 2026760

Group type: EXPERIMENTAL
Intervention: Insulin dose 0.6 mU/kg‐min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin dose 5.0 mU/kg‐min
Number of subjects: 12
Study: 7388581

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 93
Study: 30694452

Group type: EXPERIMENTAL
Intervention: Debiasing checklist
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Content (knowledge) checklist
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no checklist)
Number of subjects: 61
Study: 28732512

Group type: EXPERIMENTAL
Intervention: Prolonged admission in an acute or post-acute care facility
Number of subjects: 89

Group type: COMPARATOR
Intervention: Discharged to home
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (prolonged admission and discharged to home)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 89
Study: 25828994

Group type: EXPERIMENTAL
Intervention: Concurrent anemia and inflammation (CRP ≥ 10 mg/L)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Anemia without inflammation
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Inflammation without anemia
Number of subjects: 470

Group type: COMPARATOR
Intervention: No anemia and no inflammation
Number of subjects: 470
Study: 23713032

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no drug) during PEI after leg cycling
Number of subjects: 8

Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol) during PEI after leg cycling
Number of subjects: 8

Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate) during PEI after leg cycling
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no drug) during PEI after handgrip
Number of subjects: 8

Group type: COMPARATOR
Intervention: Parasympathetic blockade (glycopyrrolate) during PEI after handgrip
Number of subjects: 8

Group type: COMPARATOR
Intervention: β‐adrenergic blockade (metoprolol) during PEI after handgrip
Number of subjects: 8
Study: 21787392

Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention with women's groups facilitated by ASHAs
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150000
Study: 19351238

Group type: EXPERIMENTAL
Intervention: Ciclesonide therapy
Number of subjects: 0
Study: 16733237

Group type: EXPERIMENTAL
Intervention: Diet high in walnuts (20% energy) for 8 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Diet high in unsalted cashew nuts (20% energy) for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cashew group
Number of subjects: 62
Study: 15345099

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain GG (LGG) milk formula
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo milk formula
Number of subjects: 179
Study: 11753767

Group type: EXPERIMENTAL
Intervention: Single event multilevel surgery for gait improvement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiotherapy programme (Control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single event multilevel surgery
Number of subjects: 20
Study: 9405913

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8098276

Group type: EXPERIMENTAL
Intervention: Denopamine (20 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2957943

Group type: EXPERIMENTAL
Intervention: Intrahepatic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.3 mg/kg body weight per day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Systemic therapy (14-day continuous infusion of fluorodeoxyuridine at 0.15 mg/kg body weight per day)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Crossover from systemic to intrahepatic therapy after tumor progression
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Intrahepatic therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Intrahepatic group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Systemic group
Number of subjects: 162
Study: 31941381

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3044
Study: 28753030

Group type: EXPERIMENTAL
Intervention: Acupuncture and Bee Venom Acupuncture (BVA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham acupuncture and normal saline injections
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional treatment with anti-parkinsonian drugs
Number of subjects: 73
Study: 26847230

Group type: EXPERIMENTAL
Intervention: Conditional cash transfers (US$5, plus US$1 increment at every subsequent visit)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 433
Study: 25678098

Group type: EXPERIMENTAL
Intervention: Finerenone (doses ranging from 2.5 to 20.0 mg once daily)
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Eplerenone (25 mg every second day to 50 mg once daily for 90 days)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 1060
Study: 24028234

Group type: EXPERIMENTAL
Intervention: School-based tobacco control intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Delayed-intervention control
Number of subjects: 72
Study: 21921249

Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: General Dental Practitioners' (GDPs) standard restorations (control)
Number of subjects: 132
Study: 19006209

Group type: EXPERIMENTAL
Intervention: Cognition assessed by Wechsler scale subtests
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Behavior assessed by parent-questionnaires
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sleep-related breathing disorders (SRBD) assessed by polysomnography
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Performance subtest scores
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neurobehavioral abnormalities
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Association of neurobehavioral abnormalities with SRBD
Number of subjects: 31
Study: 16978997

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 2340

Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 2340
Study: 12767565

Group type: EXPERIMENTAL
Intervention: 25 microg of intravaginal misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50 microg of intravaginal misoprostol
Number of subjects: 120
Study: 10562113

Group type: EXPERIMENTAL
Intervention: Advanced nurse practitioner intervention in cardiovascular medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8804228

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasoactive agents (dopamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth factors and atrial natriuretic peptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biocompatible membranes
Number of subjects: 0
Study: 1832181

Group type: EXPERIMENTAL
Intervention: Antacids and H2-antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0
Study: 6859790

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and metoprolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30959242

Group type: EXPERIMENTAL
Intervention: Taste
Number of subjects: 35

Group type: COMPARATOR
Intervention: No Taste
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-calorie real food cues
Number of subjects: 35
Study: 29405785

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HRT)
Number of subjects: 6993

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 6993
Study: 26550687

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 100/25 μg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25155600

Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg single dose)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Boceprevir (800 mg every 8 hours for 10 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Telaprevir (750 mg every 8 hours for 10 days)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Eltrombopag (200 mg single dose with boceprevir or telaprevir)
Number of subjects: 56
Study: 22549173

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Placebo massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 20511481

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil, 1200 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 18794746

Group type: EXPERIMENTAL
Intervention: Individualized physical therapy and exercise, standardized self-training program, and back education
Number of subjects: 45

Group type: COMPARATOR
Intervention: Self-training program and back education (no individualized therapy)
Number of subjects: 45
Study: 16083789

Group type: EXPERIMENTAL
Intervention: Vaccination with genetically modified Bet v 1 derivatives (trimer and fragments)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vaccination with genetically modified Bet v 1 derivatives
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12271286

Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream, applied 3 times a week for up to 16 weeks
Number of subjects: 5
Study: 9672959

Group type: EXPERIMENTAL
Intervention: Classroom program
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Classroom program plus a semester-long school-as-community component
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1074
Study: 7852871

Group type: EXPERIMENTAL
Intervention: Purified fibrinogen from insulin-dependent diabetics
Number of subjects: 22

Group type: COMPARATOR
Intervention: Purified fibrinogen from healthy subjects
Number of subjects: 22
Study: 2810139

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training + instructions and modeling for rest position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback training + prosthetic guide (6.8 mm spacing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (biofeedback only)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24
Study: 31965526

Group type: EXPERIMENTAL
Intervention: In-person lifestyle intervention (LI)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Telephone lifestyle intervention (LI)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Medical nutrition therapy (MNT)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 208
Study: 29217129

Group type: EXPERIMENTAL
Intervention: Modified BPD‐DS with a long alimentary limb (1 m from Treitz ligament)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard BPD‐DS (strict alimentary limb of 1.5 m)
Number of subjects: 20
Study: 26720599

Group type: EXPERIMENTAL
Intervention: e-learning program (training group, n=57)
Number of subjects: 113

Group type: COMPARATOR
Intervention: no-training group (control group, n=56)
Number of subjects: 113

Group type: COMPARATOR
Intervention: no-training group (control group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: e-learning program (training group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Doctors (first test)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Midwives (first test)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Doctors (second test, training group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Midwives (second test, training group)
Number of subjects: 113
Study: 24947106

Group type: EXPERIMENTAL
Intervention: Responsive stimulation
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Enhanced nutrition
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Combination of responsive stimulation and enhanced nutrition
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Routine health and nutrition services (Control)
Number of subjects: 1489
Study: 23673269

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) infusion
Number of subjects: 2

Group type: COMPARATOR
Intervention: EP4 receptor antagonist BGC20‐1531
Number of subjects: 2

Group type: COMPARATOR
Intervention: Prostaglandin F2α (PGF2α) infusion
Number of subjects: 2
Study: 20827017

Group type: EXPERIMENTAL
Intervention: Hydrocortisone aceponate (0.127%) lipophilic cream applied twice daily
Number of subjects: 415
Study: 18221398

Group type: COMPARATOR
Intervention: GHRH + ARG (1 microg/kg body weight i.v. GHRH followed by 0.5 g/kg body weight i.v. arginine hydrochloride)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ghrelin (1 microg/kg body weight i.v. acylated ghrelin)
Number of subjects: 15
Study: 15893293

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 0
Study: 12513038

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 11377905

Group type: EXPERIMENTAL
Intervention: Hydroview IOL (Bausch & Lomb)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AcrySof IOL (Alcon)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MemoryLens IOL (ORC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CeeOn 920 IOL (Pharmacia)
Number of subjects: 100
Study: 9204355

Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 250 mg I/ml)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Diatrizoate (Urografin 219 mg I/ml)
Number of subjects: 116
Study: 8201703

Group type: EXPERIMENTAL
Intervention: Intraarterial thrombolytic therapy (urokinase)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Operative intervention
Number of subjects: 114
Study: 2444000

Group type: EXPERIMENTAL
Intervention: Cefazolin (CFZ) 4 days (16 X 0.5 g)
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Cefuroxime (CFX) 2 days (4 X 1.5 g)
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Cefazolin (CFZ) 1 day (4 X 0.5 g)
Number of subjects: 1384
Study: 2087142

Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1146747

Group type: EXPERIMENTAL
Intervention: Oral contraceptives with vitamin B6 deficiency
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vitamin B6 deficiency (Control)
Number of subjects: 13
Study: 30396006

Group type: EXPERIMENTAL
Intervention: Barley beta glucans (6 g in experimental bread)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (equal bread without beta glucans)
Number of subjects: 43
Study: 28915981

Group type: EXPERIMENTAL
Intervention: TEAS-2/100Hz
Number of subjects: 481

Group type: COMPARATOR
Intervention: TEAS-2Hz
Number of subjects: 481

Group type: COMPARATOR
Intervention: TEAS-100Hz
Number of subjects: 481

Group type: COMPARATOR
Intervention: Control
Number of subjects: 481
Study: 25873144

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CSII and MDI
Number of subjects: 316
Study: 22836615

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21177770

Group type: EXPERIMENTAL
Intervention: Intervention group (Switch-2-Activity programme)
Number of subjects: 1048
Study: 20040086

Group type: EXPERIMENTAL
Intervention: UK-2 h (20,000 U/kg for 2 hours)
Number of subjects: 129

Group type: COMPARATOR
Intervention: UK-12 h (2,200 U/kg.h for 12 hours)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: UK-2 h
Number of subjects: 129

Group type: COMPARATOR
Intervention: UK-12 h
Number of subjects: 129
Study: 17597141

Group type: EXPERIMENTAL
Intervention: Single-event children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeat-event children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress effects
Number of subjects: 0
Study: 14648009

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1172
Study: 11495617

Group type: EXPERIMENTAL
Intervention: Assistance (n = 293)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Counseling (n = 289)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Advice (n = 292)
Number of subjects: 874
Study: 9609375

Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonresorbable barrier membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Barrier-treated sites with 10% or less bacterial pathogens and free of HCMV and EBV‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Barrier-treated sites with more than 10% bacterial pathogens and/or test viruses
Number of subjects: 10
Study: 7978177

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Thiopentone anesthesia
Number of subjects: 8
Study: 3071871

Group type: EXPERIMENTAL
Intervention: Endoscopic haemostatic injection with absolute alcohol (Asaki's method)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (blood transfusions, antacids, cimetidine, pirenzepine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Postoperative mortality
Number of subjects: 80
Study: 31108918

Group type: EXPERIMENTAL
Intervention: Relative telomere length (RTL)
Number of subjects: 4944
Study: 27922030

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg, before bedtime)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo (before bedtime)
Number of subjects: 228
Study: 25524481

Group type: EXPERIMENTAL
Intervention: High viscosity bone cement (group H)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low viscosity bone cement (group L)
Number of subjects: 32
Study: 22803642

Group type: COMPARATOR
Intervention: TAK-683 (0.01-2.0 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAK-683 (0.03-1.0 mg on day 1, followed by 0.01-2.0 mg continuous infusion on days 2-13)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAK-683 (2.0 mg day(-1) continuous dosing)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAK-683 continuous dosing
Number of subjects: 60
Study: 21397402

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 4.5g per night
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 6g per night
Number of subjects: 548
Study: 18278611

Group type: EXPERIMENTAL
Intervention: HAART users
Number of subjects: 179

Group type: COMPARATOR
Intervention: HAART use
Number of subjects: 179
Study: 16447105

Group type: EXPERIMENTAL
Intervention: Gentamicin (2.5 mg/kg intramuscularly every 12 h for 7 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Doxycycline (100 mg orally for adults and 2.2 mg/kg orally for children every 12 h for 7 days)
Number of subjects: 65
Study: 14523176

Group type: EXPERIMENTAL
Intervention: Iron supplementation (high-iron and low-iron groups combined)
Number of subjects: 1657

Group type: COMPARATOR
Intervention: No-added-iron group
Number of subjects: 1657
Study: 11101069

Group type: COMPARATOR
Intervention: Zidovudine plus didanosine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine plus nevirapine
Number of subjects: 60
Study: 8833713

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (bedtime delayed until 3 a.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Reference night (normal sleep)
Number of subjects: 8